Fund selling and position decreases in Amgen

Institutional investors have recently reduced their holdings in Amgen Inc. ($AMGN), signaling a possible shift in sentiment or portfolio strategy among large shareholders.

Key developments include:

• DNB Asset Management AS sold 16,121 shares of Amgen, according to a MarketBeat report dated February 27, 2026. This transaction reflects a notable trimming of their position in the biotechnology giant.

• Primecap Management Co. CA also decreased its stake in Amgen, as reported on February 26, 2026, indicating a broader trend of position reduction among significant institutional holders.

These moves could be interpreted in several ways:

• Profit-taking: After periods of gains, some institutions may be realizing profits by selling shares.

• Portfolio rebalancing: Fund managers often adjust holdings to align with changing investment mandates or risk profiles.

• Divergent views on Amgen's outlook: The sales may reflect differing assessments among large investors regarding the company’s future growth prospects or sector dynamics.

While the exact motivations remain undisclosed, the coordinated nature of these reductions from prominent funds is noteworthy for market observers tracking institutional behavior in the healthcare sector.